Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 18/20 | 0.44 |
| ▸ | RAMP1 | O60894 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | CALCA | P06881 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491500 | 1.00 | CALCRL (0.44) | CALCRLRAMP1CYP3A4CALCACCR1 | |
| SCHEMBL6477892 | 0.89 | CALCRL (0.44) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6477898 | 0.89 | CALCRL (0.44) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6478703 | 0.89 | CALCRL (0.46) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6478705 | 0.89 | CALCRL (0.46) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6486321 | 0.88 | CALCRL (0.47) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6486317 | 0.88 | CALCRL (0.47) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6485145 | 0.87 | CALCRL (0.44) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6485140 | 0.87 | CALCRL (0.44) | CALCRLRAMP1CYP3A4CALCA | |
| SCHEMBL6479368 | 0.86 | CALCRL (0.47) | CALCRLRAMP1CYP3A4CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949541-B2 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-27 | — | — | US | claimed |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| US-6949541-B2 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | CALCA, CALCRL, P2RY1 | CALCRL 2/4885RAMP1 51/4885CYP3A4 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.